Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
List view / Grid view
Pancreatic ductal adenocarcinoma (PDAC)
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
Mice treated with a small molecule inhibitor of cadherin 11 (CDH11) had reduced pancreatic cancer growth and increased survival time.
The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.
Scientists identified a novel, highly specific drug target in the enzyme (sterol O-acyltransferase 1 (SOAT1)) cancer cells use to store cholesterol.
Researchers have developed a new cocktail of drugs that shrink pancreatic tumours in mice by blocking pathways that cancer cells use.
A protein that causes pancreatic ductal adenocarcinoma has been identified as a therapeutic target by researchers.
Scientists in California have discovered that a newly developed drug prevents pancreatic cancer in lab mice.
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Through a process involving vitamin A, researchers from Imperial College London observed that it was possible to switch off pancreatic stellate cells...